MARKET

SANA

SANA

Sana Biotechnology, Inc.
NASDAQ
3.930
+0.380
+10.70%
After Hours: 4.020 +0.09 +2.29% 19:53 02/06 EST
OPEN
3.690
PREV CLOSE
3.550
HIGH
3.995
LOW
3.685
VOLUME
3.27M
TURNOVER
--
52 WEEK HIGH
6.55
52 WEEK LOW
1.260
MARKET CAP
1.05B
P/E (TTM)
-4.0486
1D
5D
1M
3M
1Y
5Y
1D
Commit To Purchase Sana Biotechnology At $2.50, Earn 26% Using Options
NASDAQ · 3d ago
Weekly Report: what happened at SANA last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at SANA last week (0119-0123)?
Weekly Report · 01/26 09:21
Sana Biotechnology Stock: Promising T1D Science, But Wait For Dips
Seeking Alpha · 01/19 12:40
Weekly Report: what happened at SANA last week (0112-0116)?
Weekly Report · 01/19 09:23
Will UP421’s One-Year Data and 2026 Pipeline Goals Change Sana Biotechnology's (SANA) Narrative
Simply Wall St · 01/18 00:27
Sana Biotechnology (SANA) Valuation Check After J.P. Morgan Conference Cell Therapy Updates
Simply Wall St · 01/16 16:32
Bank of America Securities Reaffirms Their Buy Rating on Sana Biotechnology (SANA)
TipRanks · 01/15 11:37
More
About SANA
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.

Webull offers Sana Biotechnology Inc stock information, including NASDAQ: SANA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SANA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SANA stock methods without spending real money on the virtual paper trading platform.